Lancet 396 (10265): 1817-1828, 2020.[PUBMED Abstract] Cortes J, Rugo HS, Cescon DW, et al.: Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.
N Engl J Med 387 (3): 217-226, 2022.[PUBMED Abstract] Schmid P, Adams S, Rugo HS, et al.: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
N Engl J Med 379 (22): 2108-2121, 2018.[PUBMED Abstract] Emens LA, Adams S, Barrios CH, et al.: First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol 32 (8): 983-993, 2021.[PUBMED Abstract] Miles D, Gligorov J, Andr√© F, et al.: Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.